In the past decades, there have been significant advances in the field of immunotherapy for the treatment of cancer patients. These advances have revolutionized treatment landscapes in both solid and hematologic malignancies and improved outcomes. Among the various options of immunotherapy, bispecific antibodies represent a novel therapeutic approach integrating the action of the immune system to redirect the activation of innate and adaptive immunity toward specific antigens and specific tumor locations. Various designs and functions of bispecific antibodies for the management of solid and hematologic malignancies are being investigated in clinical trials. Some have shown promising results with improvements in outcomes of multiple cancers and have resulted in FDA approvals. However, we are also now facing new challenges associated with bispecific antibodies, including management of adverse events and mechanisms of resistance.
We invite the community to contribute articles focused on bispecific antibodies in solid and hematologic malignancies. Papers should narrate the current state of the art in bispecific antibody therapeutics, challenges, and opportunities, and speculate on evolving avenues for the field. We welcome original research and review articles.
We are particularly interested in the following topics:
- Overview of bispecific antibody platforms (Fc engineering, heavy and light chain pairing methodologies, high throughout product methods, etc)
- Clinical development experience on bispecific antibodies in solid tumors (safety and tolerability, immunogenicity, biomarkers, and/or bioanalytic assay development)
- Clinical development experience on bispecific antibodies in hematologic malignancies (safety and tolerability, immunogenicity, biomarkers, and/or bioanalytic assay development)
- Review on development of bispecific molecules and manufacturing considerations (bispecific design, challenges in cell line development, etc)
About the Guest Advisor team:
Dr. Carlyn Tan is a board-certified hematologist and oncologist specializing in the treatment of multiple myeloma and other related plasma cell disorders. She is part of a multidisciplinary team at Memorial Sloane Kettering Cancer Center caring for people with these conditions, and her research interests include the development of innovative therapeutic approaches for the management of multiple myeloma and the exploration of biomarkers to predict and track responses to these therapies. Dr. Tan is involved in a number of clinical trials evaluating novel therapeutic approaches for the treatment of multiple myeloma.
Dr. Neha S. Korde is an Associate Attending Physician at Memorial Sloane Kettering Cancer Center, specializing in the treatment of multiple myeloma and other plasma cell neoplasms. She has a particular research interest in early plasma cell disorders, including monoclonal gammopathy of unknown significance (MGUS) and smoldering myeloma (SMM), and understanding disease biology that may promote transition to frank symptomatic multiple myeloma in some individuals.
For more information about this Collection, please contact Cassie Houtz at [email protected].
